Market Price

47.18 

0.22 0.5%

as of Jun 06 '23

52 Week Range:

41.55 103.96


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 1.53
1.69
1.59
2.60
3.43
4.01
4.21
4.72
5.44
5.50
7.81
growth rate 10.5% -5.9% 63.5% 31.9% 16.9% 5.0% 12.1% 15.3% 1.1% 42.0%
Earnings BIT 494.80
642.90
819.40
1,022.40
1,072.80
1,238.50
1,316.20
1,586.50
growth rate 29.9% 27.5% 24.8% 4.9% 15.5% 6.3% 20.5%
Avg.PE 32.35
40.47
39.15
39.15
39.15
39.15
growth rate 25.1% -3.3% 0.0% 0.0% 0.0%
ROA 12.63
13.96
15.84
25.96
13.05
13.29
11.44
13.11
17.73
12.00
19.10
growth rate 10.5% 13.5% 63.9% -49.7% 1.8% -13.9% 14.6% 35.2% -32.3% 59.2%
ROE 17.89
20.82
25.78
43.25
21.08
22.24
20.94
23.69
28.73
18.88
28.88
growth rate 16.4% 23.8% 67.8% -51.3% 5.5% -5.9% 13.1% 21.3% -34.3% 53.0%
ROIC 16.05
18.56
20.71
33.14
17.05
17.60
14.58
20.21
24.14
16.18
25.50
growth rate 15.6% 11.6% 60.0% -48.6% 3.2% -17.2% 38.6% 19.5% -33.0% 57.6%
Cur. Ratio 3.49
3.72
4.99
5.28
4.30
4.21
1.80
2.61
3.31
3.46
3.08
growth rate 6.6% 34.1% 5.8% -18.6% -2.1% -57.2% 45.0% 26.8% 4.5% -11.0%
Quick Ratio 2.30
2.50
3.66
4.06
3.29
3.17
1.28
1.70
2.34
2.24
2.06
growth rate 8.7% 46.4% 10.9% -19.0% -3.7% -59.6% 32.8% 37.7% -4.3% -8.0%
Leverage 1.48
1.50
1.75
1.61
1.62
1.72
1.93
1.70
1.56
1.58
1.46
growth rate 1.4% 16.7% -8.0% 0.6% 6.2% 12.2% -11.9% -8.2% 1.3% -7.6%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 325.00
371.80
414.60
479.30
537.30
599.10
602.80
664.90
growth rate 14.4% 11.5% 15.6% 12.1% 11.5% 0.6% 10.3%
Acct.Payable 58.20
63.90
97.10
116.60
134.00
180.40
196.50
204.50
growth rate 9.8% 52.0% 20.1% 14.9% 34.6% 8.9% 4.1%
Cur.Assets 2,231.10
2,047.90
2,240.00
2,549.20
2,286.90
2,984.00
3,091.00
3,180.70
growth rate -8.2% 9.4% 13.8% -10.3% 30.5% 3.6% 2.9%
Total Assets 3,523.00
4,056.30
4,510.00
5,666.40
5,323.70
6,488.10
7,237.10
8,502.60
growth rate 15.1% 11.2% 25.6% -6.1% 21.9% 11.5% 17.5%
Cash 653.80
718.40
930.10
818.30
714.10
1,179.10
1,183.20
862.80
growth rate 9.9% 29.5% -12.0% -12.7% 65.1% 0.4% -27.1%
Inventory 296.80
339.90
396.60
554.90
607.00
640.90
802.30
726.70
growth rate 14.5% 16.7% 39.9% 9.4% 5.6% 25.2% -9.4%
Cur.Liabilities 426.10
476.20
532.50
1,420.00
876.60
902.40
893.90
1,032.30
growth rate 11.8% 11.8% 166.7% -38.3% 2.9% -0.9% 15.5%
Liabilities 1,331.60
1,553.20
1,891.00
2,710.20
2,183.30
2,339.80
2,662.80
2,666.70
growth rate 16.6% 21.8% 43.3% -19.4% 7.2% 13.8% 0.2%
LT Debt 598.10
596.90
822.30
438.40
593.80
594.40
595.00
595.70
growth rate -0.2% 37.8% -46.7% 35.5% 0.1% 0.1% 0.1%
Equity 2,191.40
2,503.10
2,619.00
2,956.20
3,140.40
4,148.30
4,574.30
5,835.90
growth rate 14.2% 4.6% 12.9% 6.2% 32.1% 10.3% 27.6%
Common Shares 716.00
709.00
682.00
651.00
660.00
653.00
648.00
215.20
218.10
636.40
642.00
growth rate -1.0% -3.8% -4.6% 1.4% -1.1% -0.8% -66.8% 1.4% 191.8% 0.9%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 82.90
102.70
176.10
168.10
238.70
254.40
407.00
325.80
growth rate 23.9% 71.5% -4.5% 42.0% 6.6% 60.0% -20.0%
Cash From OA 1,022.30
549.70
704.40
1,000.70
926.70
1,182.90
1,054.30
1,732.10
growth rate -46.2% 28.1% 42.1% -7.4% 27.7% -10.9% 64.3%
FCF per Share 0.20
0.25
0.36
1.22
0.59
0.59
0.84
1.03
1.14
0.89
1.96
growth rate 25.0% 44.0% 238.9% -51.6% 0.0% 42.4% 22.6% 10.7% -21.9% 120.2%
Sale Purchase of Stock 113.30
87.20
103.30
113.80
growth rate -23.0% 18.5% 10.2%
FCF 224.00
246.00
363.00
929.00
443.00
487.00
825.00
685.00
901.00
647.00
1,402.00
growth rate 9.8% 47.6% 155.9% -52.3% 9.9% 69.4% -17.0% 31.5% -28.2% 116.7%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 2,322.90
2,493.70
2,963.70
3,435.30
3,722.80
4,348.00
4,386.30
5,232.50
growth rate 7.4% 18.9% 15.9% 8.4% 16.8% 0.9% 19.3%
Op.Income 494.80
642.90
819.40
1,022.40
1,072.80
1,238.50
1,316.20
1,586.50
growth rate 29.9% 27.5% 24.8% 4.9% 15.5% 6.3% 20.5%
IBT 1,144.00
622.40
737.90
1,034.90
761.40
1,166.50
916.70
1,702.00
growth rate -45.6% 18.6% 40.3% -26.4% 53.2% -21.4% 85.7%
Net Income 811.10
494.90
569.50
583.60
722.20
1,046.90
823.40
1,503.10
growth rate -39.0% 15.1% 2.5% 23.8% 45.0% -21.4% 82.6%
EPS 0.33
0.41
0.57
1.25
0.75
0.87
0.90
1.13
1.64
1.30
2.38
growth rate 24.2% 39.0% 119.3% -40.0% 16.0% 3.5% 25.6% 45.1% -20.7% 83.1%
Gross Profit 1,699.30
1,876.50
2,166.30
2,560.00
2,783.40
3,233.60
3,305.70
3,983.60
growth rate 10.4% 15.4% 18.2% 8.7% 16.2% 2.2% 20.5%
R&D 346.50
382.90
442.20
552.60
622.20
752.70
760.70
903.10
growth rate 10.5% 15.5% 25.0% 12.6% 21.0% 1.1% 18.7%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 441.90
396.10
363.10
443.00
444.70
growth rate -10.4% -8.3% 22.0% 0.4%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 700.30
664.20
664.90
686.20
679.20
growth rate -5.2% 0.1% 3.2% -1.0%
Acct.Payable 144.60
139.50
204.50
158.80
162.50
growth rate -3.5% 46.6% -22.4% 2.3%
Cur.Assets 3,322.90
3,515.50
3,180.70
3,241.30
3,263.10
growth rate 5.8% -9.5% 1.9% 0.7%
Total Assets 7,662.10
8,160.30
8,502.60
8,419.90
8,425.10
growth rate 6.5% 4.2% -1.0% 0.1%
Cash 1,312.80
1,506.90
862.80
1,030.90
1,198.10
growth rate 14.8% -42.7% 19.5% 16.2%
Inventory 759.50
737.80
726.70
730.60
740.00
growth rate -2.9% -1.5% 0.5% 1.3%
Cur.Liabilities 886.20
966.50
1,032.30
949.90
969.10
growth rate 9.1% 6.8% -8.0% 2.0%
Liabilities 2,528.80
2,619.00
2,666.70
2,575.00
2,481.50
growth rate 3.6% 1.8% -3.4% -3.6%
LT Debt 595.40
595.50
595.70
595.90
596.00
growth rate 0.0% 0.0% 0.0% 0.0%
Equity 5,133.30
5,541.30
5,835.90
5,844.90
5,943.60
growth rate 8.0% 5.3% 0.2% 1.7%
Common Shares 640.10
641.20
642.00
642.90
645.00
growth rate 0.2% 0.1% 0.1% 0.3%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 69.30
60.70
89.80
72.70
43.10
growth rate -12.4% 47.9% -19.0% -40.7%
Cash From OA 526.10
531.90
373.60
293.30
332.20
growth rate 1.1% -29.8% -21.5% 13.3%
Sale Purchase of Stock
growth rate
FCF 456.80
471.20
283.80
220.60
289.10
growth rate 3.2% -39.8% -22.3% 31.1%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 1,376.00
1,310.20
1,329.70
1,341.20
1,373.90
growth rate -4.8% 1.5% 0.9% 2.4%
Op.Income 441.90
396.10
363.10
443.00
444.70
growth rate -10.4% -8.3% 22.0% 0.4%
IBT 545.50
390.90
376.30
436.10
464.70
growth rate -28.3% -3.7% 15.9% 6.6%
Net Income 489.50
340.10
335.30
373.60
406.40
growth rate -30.5% -1.4% 11.4% 8.8%
Gross Profit 1,041.70
998.50
1,020.20
1,041.90
1,104.50
growth rate -4.2% 2.2% 2.1% 6.0%
R&D 225.30
238.00
232.80
228.60
250.80
growth rate 5.6% -2.2% -1.8% 9.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (97.71)

YOY Growth Grade:

C (63.86)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 61.80 42.05 26.77
EPS / Growth 25.8% 1.12 16.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 19.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 16.1% 20.4% 20.4%
Future PE 26.77 43.13 43.13
Future EPS 5.00 7.19 7.19
Value Price
MOS %
33.07
-29.9%
76.64
62.4%
76.64
62.4%
MOS Price 16.53 38.32 38.32
IRT 12.86 11.26 11.26

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.